
usd aug pm et
summari make diagnost product medic imag system surgic product
emphasi women health also make medic aesthet system
nm price-to-earnings oper ep
risk assess reflect particip
industri character rapid technolog chang new
industri standard new market entrant addit
compet number compani
significantli greater resourc product depth
includ ge siemen phillip fuji kodak toshiba
howev maintain healthi reput solid
market share breast imag gynecolog
nov ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
lift target
base forward price-to-earnings multipl
ep estim
rais sep ep estim
ep
jun-q ep vs
estim sale rose
constant currenc cc
million ahead expect driven
global cc growth global molecular
acquisit faxitron focal
acceler growth gyn surgic
busi sale outsid
 grew cc slower recent quarter
macroeconom polit
challeng compani latin american
unlik previou quarter -- adjust
bp due sever one-tim item --
yoy jun-q /kevin huang cfa
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop manufactur supplier premium diagnost
product medic imag system surgic product emphasi women health
oper five segment diagnost total revenu year end septemb
breast health medic aesthet gyn surgic skelet health
sell servic product combin direct sale servic personnel network
independ distributor sale repres segment made total revenu
remain fy revenu came servic
offer wide rang diagnost product use primarili aid diagnosi human
diseas primari diagnost product includ holx aptima famili assay thinprep system
rapid fetal fibronectin test
breast health product includ broad portfolio breast imag relat product accessori
includ digit mammographi system computer-aid detect cad mammographi
minim invas breast biopsi devic breast biopsi site marker breast biopsi guidanc system
holx advanc breast imag platform dimens util technolog call tomosynthesi
produc imag show multipl contigu slice imag breast
medic aesthet segment offer portfolio aesthet treatment system sculpsur
enabl plastic surgeon dermatologist medic practition perform non-invas
minim invas procedur remov hair treat vascular benign pigment lesion remov
multi-color tattoo revit skin reduc fat laser lipolysi reduc cellulit clear nail
infect toe fungu ablat sweat gland improv gynecolog health
gyn surgic segment make product aim toward gynecolog health novasur
endometri ablat system skelet health segment offer product bone densitomet
imag system use assist perform minim invas surgic procedur
competit landscap holx wide array product face competit varieti
competitor includ competitor even broader product portfolio great brand recognit
current environ manag care economically-motiv buyer consolid among
healthcar provid increas competit declin reimburs rate
increasingli requir compet basi price valu reliabl effici
impact major develop major develop fiscal although
compani made sever tuck-in acquisit latest major develop march
acquir cynosur inc develop manufactur supplier broad array light-bas
aesthet medic treatment system product use provid divers rang treatment
applic non-invas bodi contour hair remov tattoo remov skin revit
scar reduct well treatment vascular lesion cynosur busi refer
medic aesthet oper separ busi segment
januari divest blood screen busi grifol sale price
billion august acquir gen-prob lead maker molecular diagnost product
billion june acquir tct intern co ltd privat held distributor
medic product china acquisit tct provid establish nationwid sale
organ custom support infrastructur china
financi trend revenu grew billion fy sep billion prior year
five-year compound annual growth rate compound-annual-growth-rate adjust earn per share fy
vs fy five-year compound-annual-growth-rate adjust ep fy free cash flow defin
cash flow oper less capit expenditur million compar neg
million fy given net debt total capit ratio decemb expect
make larg acquisit near futur howev think opportunist tuck-in acquisit
like
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rais target below-p
ep estim multipl near middl
five-year averag ratio jun-q ep vs higher
estim rais fy sep ep lower
fy ep jun-q sale increas constant
currenc million driven growth breast health intern
busi breast health sale grew constant currenc
intern busi grew exclud acquir cynosur busi
constant currenc august announc departur cfo
bob mcmahon agil result chief account offic karleen oberton
promot cfo also announc acquisit faxitron leader
digit specimen radiographi million expect continu make
tuck-in acquisit like near futur /kevin huang cfa
lower target below-p
ep estim multipl close holx
five-year averag mar-q ep vs lower
estim sep ep estim remain unchang
sale increas million howev due
signific churn holx salesforc aggress forecast
charg mar-q relat recent acquir cynosur busi
revenu growth guidanc reduc
posit note intern revenu grew organ constant
currenc basi diagnost revenu exclud divest blood screen
busi declin breast health grew gyn surgic declin
holx capit alloc strategi expect compani
focu tuck-in acquisit supplement exist busi /kevin
analyst research note compani news
et cfra maintain hold opinion share inc
lift target base forward price-to-earnings
multipl ep estim rais
sep ep estim ep
jun-q ep vs estim sale rose
constant currenc cc million ahead
expect driven global cc growth global molecular
diagnost busi recent tuck-in acquisit faxitron focal
acceler growth gyn surgic busi sale
outsid grew cc slower recent quarter
macroeconom polit challeng compani latin american busi
primarili breast health focus unlik previou quarter --
adjust oper margin declin basi point bp due sever
one-tim item -- adjust oper margin improv bp yoy
jun-q /kevin huang cfa
et cfra keep hold opinion share inc
lift target base multipl
ep estim multipl equal
averag forward price-to-earnings ratio adjust fy sep ep estim
mar-q ep vs equal estim sale rose
constant currenc cc million slightli
ahead expect led global cc growth breast health
busi follow cc growth diagnost exclud blood
busi adjust oper margin deterior basi point
mar-q primarili declin gross margin
neg affect sever one-tim item inventori reserv scrap
charg unfavor foreign exchang movement also wrote-down
million asset medic aesthet busi mar-q respons
neg trend compani previous note /kevin huang cfa
et cfra keep hold opinion share inc
maintain target ep
multipl near middl averag ratio
keep fy sep ep estim fy ep
dec-q ep vs higher estim sale rose
slightli ahead expect driven growth breast health
increas global molecular diagnost posit view
intern revenu growth constant currenc
point hurt less favor geograph product sale mix posit
view closur acquisit strengthen
posit breast-conserv surgeri see progress breast health
global molecular diagnost support top-lin growth
excess deploy support tuck-in acquisit share repurchas
et cfra retain hold opinion share inc
maintain target ep
estim multipl near middl averag
ratio sep-q ep vs lower estim
lower fy sep ep initi fy
ep sep-q sale increas constant currenc
million difficult comparison divestitur
blood screen busi non-recurring royalti revenu molecular
aesthet declin cc gyn surgic grew cc
acquir cynosur busi continu headwind due unfavor
fda letter also announc two tuck-in acquisit faxitron focal
therapeut intend continu priorit tuck-in acquisit
capit alloc /kevin huang cfa
et cfra retain hold opinion share inc
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
